• Title, Summary, Keyword: 조혈모세포이식

Search Result 107, Processing Time 0.032 seconds

The Levels of Anxiety and Depression according tn the Stages of Autologous and Allogeneic Hemopoietic Stem Cell Transplantation (자가 및 동종 조혈모세포이식환자의 이식단계에 따른 불안과 우울)

  • Choi, So-Eun;Lee, So-Young;Park, Hae-Ryung;Park, Ho-Ran
    • Journal of Hospice and Palliative Care
    • /
    • v.8 no.2
    • /
    • pp.190-199
    • /
    • 2005
  • Purpose: Objectives of this study was to investigate the level of anxiety and depression according to the stages of autologous and allogeneic hematopoietic stem cell transplantation (HSCT). It would be provide the basis for effective psycho-emotional nursing intervention. Methods: We report on 52 patients, including 19 with autologous HSCT, and 33 with allogeneic HSCT from August 2002 to August 2003, at a university hospital. Spielberger's State-Trait Anxiety Inventory and Jung's Depression Inventory were used to measure levels of anxiety and depression, respectively, at admission time, the day before HSCT, and discharge time. Data was analyzed using SAS program that included Chi-square test, Fisher's exact test, repeated measures ANOVA and Stepwise multiple regression analysis. Results: In all stages of HSCT, the level of anxiety of patients who underwent allogeneic HSCT was significantly higher than that of autologous HSCT (P=0.047). The depression at the day before HSCT was significantly higher than that at admission. The major variable affecting anxiety in autologous HSCT was depression. Specially depression and gender were significant predictors to explain anxiety in allogeneic HSCT at admission time (61%). Experience of relapse and gender were significant predictors to explain anxiety in allogeneic HSCT at discharge time (36%). Conclusion: We recommend that the anxiety and depression be researched during the stages of allogeneic HSCT, specifically in the day before HSCT. It is necessary to develop an effective psycho-emotional nursing intervention according to the stages of HSCT.

  • PDF

중국조혈모세포은행

  • Korea Marrow Donor Program
    • 나누는사람들
    • /
    • /
    • pp.20-21
    • /
    • 2007
  • 중국조혈모세포은행(CMDP)은 1992년 창립 이후 중국 홍십자회의 관리 하에 운영되어지고 있으며 기증희망자들의 모집, HLA(조직적합성항원형) 데이터입력, 예비검색, 이식등의 일을하고있다. 전문병원과 HLA검사연구실의 전문가들로 구성되어진 위원회는 중국조혈모세포은행의 발전에 중요한 역할을 하고 있다. 중국조혈모세포은행의 예산은 주로 국영자선복권의 기금과 사회적인 도움으로 이뤄진다. 중국조혈모세포은행은 경영팀, 기증자업무팀, 과학기술팀, 교육팀 등 총 4개의 팀으로 구성되어있다. 2007년 1월말 기준 전국에 30개의 기증희망자등록지부와 25개의 HLA검사실 및 정도 관리 검사실을 가지고 있고, 50만 명 이상의 기증희망자가 등록되어 있으며, 1996년 국내 최초 비혈연 조혈모세포이식 후 583건의 이식을 하였다.

  • PDF

A convergence study about Influences of hematopoietic stem cell transplantation on children growth (소아암 환아의 조혈모세포이식 후 성장에 관한 융합 연구)

  • Lim, Su-Jin
    • Journal of the Korea Convergence Society
    • /
    • v.8 no.4
    • /
    • pp.49-57
    • /
    • 2017
  • This is a convergence study about influences of hematopoietic stem cell transplantation on children growth. For this explanatory survey research, data were collected with medical record of 112 children with malignant and hematological diseases received HSCT from February to March, 2009. To analyze the growth after HSCT, mixed-effects model was used. The mean SDS of height and weight were negative values in HSCT. The mean value of SDS were significantly lower in autologous HSCT group by height(p=0.0008) and weight(p= 0.0012). Significant factors on changes of SDS of height growth were age at HSCT(p=0.0251), autologous HSCT(p=0.0020) and total dose of steroid in allogeneic HSCT (p=0.0403) and age at HSCT(p=0.0042), autologous HSCT(p=0.0035), and duration of TPN(p=0.0159) for weight growth. According to the results, we must learn to recognize the predicting growth impairment after HSCT in children. regarding nursing interventions should be conducted in the care of these children.

"징검다리"소식

  • Korea Marrow Donor Program
    • 나누는사람들
    • /
    • /
    • pp.23-23
    • /
    • 2005
  • '징검다리'는 조혈모세포이식이 필요한 환자들에게 비혈연간 조혈모세포기증을 실천한 분들의 모임입니다. 따뜻한 마음을 가진 기증자들의 모임이니 만큼 따뜻한 활동들을 하고 있습니다.

  • PDF

Second allogeneic hematopoietic stem cell transplantation in children to overcome graft failure or relapse after initial transplant (조혈모세포이식 후 생착 실패나 재발한 소아환자에서 2차 이식의 의의)

  • Kim, Dong-Yeon;Kim, Do Kyun;Kim, Soo Young;Kim, Seok Joo;Han, Dong Gyun;Baek, Hee Jo;Kook, Hoon;Hwang, Tai-Ju
    • Clinical and Experimental Pediatrics
    • /
    • v.49 no.12
    • /
    • pp.1329-1339
    • /
    • 2006
  • Purpose : Failure of hematopoietic stem cell transplantation(HSCT) may be encountered in practice because of either relapse of the malignancy or dysfunction of the graft. Second HSCT may be the only option for some patients whose initial HSCT failed. Methods : From May, 1991 to December, 2004, 115 HSCTs were performed at the Pediatric Blood & Marrow Transplantation Center, Chonnam National University. This study was a retrospective analysis of the medical records of 15 patients who received the second HSCT after initial graft. Results : Among eight patients with nonmalignant diseases, two patients underwent the second HSCT because of primary graft failure and five because of late graft rejection. The remaining Fanconi anemia patient was re-transplanted due to development of AML. Two patients died and one experienced primary graft failure, but is still alive. The Kaplan-Meier 5-year overall survival rate was 75 percent and the disease free survival rate was 62.5 percent in nonmalignant diseases. All malignant patients underwent second transplants because of relapses. Four died of relapse and one of treatment-related complications. The Kaplan-Meier 2-year overall and event free survival rate was 28.6 percent each in malignant diseases. Conclusion : Second HSCT for graft dysfunction of nonmalignant disease seems to be feasible and should be considered as a standard practice. The relapse of malignant diseases remains a big obstacle even after the second HSCT, although a small portion of patients might be salvaged. Further investigation of novel therapeutic strategies, as well an the understanding of the biology should be explored.